# **Smith**Nephew

GRAFIX<sup>°</sup> Cryopreserved Placental Membrane helped to achieve 100% wound granulation and complete wound closure in patients with complex, chronic diabetic foot ulcers (DFUs)



### Overview

Results

- Multicenter, open-label, single-arm, 17-week study
- Patients had a complex DFU (longest diameter, ≤15cm; mean duration, 7.5 months; mean area, 14.6cm<sup>2</sup>) extending through the dermis and into subcutaneous tissue with evidence of exposed muscle, tendon, fascia, bone and/or joint capsule
  - 68% had failed to close with ≥1 prior advanced treatment

- 100% granulation of DFUs (primary endpoint) was achieved

in 96.3% of the PP population (83.9% ITT; Figure), within a mean of 6.8 weeks (ie, 6.8 GRAFIX Membrane applications)

- Complete wound closure was achieved in 59.3% of patients

In the PP population, mean percentage wound area reduction was 54.3% at Day 28, 72.8% at Week 8 and 92.3% at the end of

in the PP population (51.6% ITT; Figure), within a mean of 9.1

At 16 weeks post-initial GRAFIX Membrane application:

weeks (ie, 9.0 GRAFIX Membrane applications)

- Patients received weekly GRAFIX Membrane for up to 16 weeks
  - Standard wound care was off-loading, weekly wound cleansing and debridement prior to GRAFIX Membrane application
- In total, 31 patients were included in the study, forming the intention-to-treat (ITT) population

Of these, 27 completed the entire study (PP population)



Figure. Patients (%) in the PP (n=27) and ITT populations (n=31) achieving 100% granulation and complete wound closure at 16 weeks post-initial **GRAFIX** Membrane application

# Conclusions

the study

## Citation

\*Frykberg RG, Gibbons GW, Walters JL, Wukich DK, Milstein FC. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. Int Wound J. 2017;14(3):569-577.

#### Available from: International Wound Journal 🕣

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Study sponsored by Osiris Therapeutics Inc, which is now a wholly owned direct subsidiary of Smith & Nephew Consolidated, Inc. Advanced Wound Management, Smith & Nephew, Inc. Fort Worth, TX 76109 USA | GRAFIX Customer Care Center: T 888-674-9551 F 443-283-4419 | OSiris, GRAFIX, GRAFIXPL, GRAFIX PRIME, GRAFIX CORE, GRAFIXXC, and GRAFIXPL PRIME are trademarks of Osiris Therapeutics, Inc., a wholly owned direct subsidiary of Smith & Nephew Consolidated, Inc. | ©2022 Smith & Nephew, Inc. | ©2022 Smith & Nephew, Inc. | Osiris, GRAFIXPL, GRAFIX www.smith-nephew.com/education